Project description
Novel 3D cell culture platform to substitute animals in the preclinical testing
More than 85 % of early clinical trials currently fail despite promising results in preclinical in vitro testing. The main reason is associated with in vitro 2D cell cultures that do not recapitulate the living body environment. Consequently, preclinical animal testing remains a benchmark, despite the associated cost and ethical concerns. The Czech company InoCure is developing a unique 3D scaffolding platform for in vitro cell culture with a drug delivery embedded system. The goal is to significantly improve preclinical-to-clinical translation efficiency while providing an alternative to animal testing models. The EU-funded DifMATRIX project aims to accomplish the feasibility study, evaluating the legal, economic and technical viability of the technology introduction to the market.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesclinical medicineoncology
- natural sciencesbiological sciencesmolecular biology
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1
Coordinator
11000 Praha
Czechia
See on map